<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31776871</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1179-1934</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>33</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>CNS drugs</Title>
          <ISOAbbreviation>CNS Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.</ArticleTitle>
        <Pagination>
          <StartPage>1201</StartPage>
          <EndPage>1222</EndPage>
          <MedlinePgn>1201-1222</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40263-019-00683-7</ELocationID>
        <Abstract>
          <AbstractText>This article provides an overview of the pharmacokinetic drug-drug interactions (DDIs) for agents prescribed for attention-deficit/hyperactivity disorder (ADHD). Polypharmacy in the treatment of patients with ADHD leads to high exposures to DDIs and possibly adverse safety outcomes. We performed a systematic search of DDI reports for ADHD agents in Embase and Medline. We also searched for agents in the pharmacological pipeline, which include (1) mazindol, molindone and viloxazine, which were previously prescribed for other indications; (2) centanafadine and AR-08, never before approved; and (3) two extracts (Polygala tenuifolia extract and the French maritime pine bark extracts). The identified literature included case reports, cross-sectional, cross-over and placebo-controlled studies of patient cohorts and healthy volunteers. The DDIs were classified as follows: ADHD agents acting as perpetrators, i.e., affecting the clearance of co-prescribed agents (victim drugs), or ADHD agents being the victim drugs, being affected by other agents. Ratios for changes in pharmacokinetic parameters before and after the DDI were used as a rough estimate of the extent of the DDI. Alcohol may increase plasma dextroamphetamine concentrations by presystemic effects. Until studies are done to orient clinicians regarding dosing changes, clinicians need to be aware of the potential for cytochrome P450 (CYP) 2D6 inhibitors to increase amphetamine levels, which is equivalent to increasing dosages. Atomoxetine is a wide therapeutic window drug. The CYP2D6 poor metabolizers who do not have CYP2D6 activity had better atomoxetine response, but also an increased risk of adverse effects. CYP2D6 inhibitors have been used to increase atomoxetine response in CYP2D6 extensive metabolizers. Guanfacine is mainly metabolized by CYP3A4, which can be induced and inhibited. The package insert recommends that in guanfacine-treated patients, after adding potent CYP3A4 inducers, the guanfacine dose should be doubled; after adding potent CYP3A4 inhibitors the guanfacine dose should be halved. Based on a phenobarbital case report and our experience with CYP3A4-metabolized antipsychotics, these correction factors may be too low. According to two case reports, carbamazepine is a clinically relevant inducer of methylphenidate (MPH). A case series study suggested that MPH may be associated with important elevations in imipramine concentrations. Due to the absence of or limitations in the data, no comments for clinicians can be provided on the pharmacokinetic DDIs for clonidine, centanafadine, mazindol, molindone, AR-08, P. tenuifolia extract and the French maritime pine bark extracts. According to currently available data, clinicians should not expect that ADHD drugs modify each other's serum concentrations. A summary table for clinicians provides our current recommendations on pharmacokinetic DDIs of ADHD agents based on our literature review and the package inserts; whenever it was possible, we provide information on serum concentrations and dose correction factors. There will be a need to periodically update these recommendations and these correction factors as new knowledge becomes available.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schoretsanitis</LastName>
            <ForeName>Georgios</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-3851-4117</Identifier>
            <AffiliationInfo>
              <Affiliation>The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Leon</LastName>
            <ForeName>Jose</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-7756-2314</Identifier>
            <AffiliationInfo>
              <Affiliation>University of Kentucky Mental Health Research Center at Eastern State Hospital, Lexington, KY, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apostol Hospital, University of the Basque Country, Vitoria, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eap</LastName>
            <ForeName>Chin B</ForeName>
            <Initials>CB</Initials>
            <Identifier Source="ORCID">0000-0002-5439-0230</Identifier>
            <AffiliationInfo>
              <Affiliation>Unit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Centre for Psychiatric Neuroscience, Lausanne University Hospital, Hospital of Cery, University of Lausanne, Prilly, Switzerland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmaceutical Sciences of Western, Switzerland University of Geneva, Geneva, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kane</LastName>
            <ForeName>John M</ForeName>
            <Initials>JM</Initials>
            <Identifier Source="ORCID">0000-0002-2628-9442</Identifier>
            <AffiliationInfo>
              <Affiliation>The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Hofstra Northwell School of Medicine, Hempstead, NY, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Feinstein Institute for Medical Research, Manhasset, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paulzen</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-4198-5160</Identifier>
            <AffiliationInfo>
              <Affiliation>Alexianer Hospital Aachen, Alexianergraben 33, 52062, Aachen, Germany. m.paulzen@alexianer.de.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, Germany. m.paulzen@alexianer.de.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>JARA-Translational Brain Medicine, Aachen, Germany. m.paulzen@alexianer.de.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>CNS Drugs</MedlineTA>
        <NlmUniqueID>9431220</NlmUniqueID>
        <ISSNLinking>1172-7047</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.1</RegistryNumber>
          <NameOfSubstance UI="D019389">Cytochrome P-450 CYP2D6</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019389" MajorTopicYN="N">Cytochrome P-450 CYP2D6</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31776871</ArticleId>
        <ArticleId IdType="doi">10.1007/s40263-019-00683-7</ArticleId>
        <ArticleId IdType="pii">10.1007/s40263-019-00683-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pharmacol Biochem Behav. 2006 Sep;85(1):29-38</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16916538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurology. 1971 Nov;21(11):1123-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5166217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cochrane Database Syst Rev. 2018 May 09;5:CD012069</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29744873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychoneuroendocrinology. 2016 Nov;73:9-15</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27448523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arzneimittelforschung. 2010;60(5):238-44</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20533759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trials. 2017 Mar 28;18(1):145</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28351412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Ther. 2016 Oct 6;38(10S):e23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27673638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Pharmacol Exp Ther. 2004 Feb;308(2):410-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14610241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacol Res. 1989 Jan-Feb;21(1):111-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2498859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alcohol Clin Exp Res. 1992 Feb;16(1):75-81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1558306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epilepsia. 1984 Aug;25(4):482-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6745218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1972 Mar-Apr;13(2):201-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4552820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ther Drug Monit. 1988;10(3):359-60</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3176117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 2002 Nov;42(11):1219-27</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12412820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Expert Rev Clin Pharmacol. 2018 Jun;11(6):625-639</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29776316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pediatrics. 2011 Nov;128(5):1007-22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22003063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 1998 Mar;38(3):276-82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9549666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Neurol Neurosurg Psychiatry. 1986 Oct;49(10):1142-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3783175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Psychiatry. 2006 Apr;67(4):611-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16669726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Clin Pharmacol. 1983;25(4):463-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6360692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 2007 Mar;81(3):346-53</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17339864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Neurol Neurosurg Psychiatry. 1992 Feb;55(2):126-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1538217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clujul Med. 2015;88(4):513-20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26733750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychiatr Serv. 2015 Apr 1;66(4):404-10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25828983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CNS Drugs. 2010 Dec;24(12):1009-25</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21090837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Psychopharmacol. 2007 Jun;27(3):241-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17502769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pediatr (Phila). 2015 Apr;54(4):376-81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25305264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postgrad Med. 2009 Sep;121(5):11-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19820270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nephron. 1995;71(1):105</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8538830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curr Pharmacogenomics Person Med. 2012 Mar;10(1):22-32</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23467392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):915-24</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16113620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Am Acad Child Adolesc Psychiatry. 2014 Sep;53(9):960-970.e2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25151419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Gravit Physiol. 2007 Jul;14(1):P107-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18372722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Psychiatry Clin Pract. 2016;20(2):70-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27052374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Psychiatry. 2017 Jul;78(7):e744-e781</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28686819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CNS Drugs. 2004;18(4):243-50</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15015904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Expert Opin Drug Metab Toxicol. 2016;12(4):407-22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26878495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neuropsychiatr Dis Treat. 2010 Jun 24;6:317-27</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20628632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Pharm Pharm Sci. 2016 Apr-Jun;19(2):198-207</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27518170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sleep Med. 2013 Jan;14(1):30-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23036267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Psychiatry. 1971 Jun;127(12):1619-25</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4998422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CNS Drugs. 2014 Jun;28(6):497-511</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24788672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Addict Med. 2012 Dec;6(4):265-73</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22987022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur Addict Res. 2018;24(1):43-51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29510390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Psychopharmacol. 2017 Aug;37(4):419-428</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28590363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Am Pharm Assoc (2003). 2006 Jul-Aug;46(4):472-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16913391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CNS Drugs. 2014 Feb;28(2):121-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24402970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Neuropsychopharmacol. 2010 Oct;13(9):1193-205</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20047711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 1998 Oct;38(10):971-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9807980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JAMA. 1969 Mar 17;207(11):2053-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5818377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ther Drug Monit. 1989 Sep;11(5):520-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2815226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xenobiotica. 1975 Feb;5(2):113-29</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1154799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acta Neurol Scand. 1994 Aug;90(2):130-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7801739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Pharm Sci. 2016 Jun 30;89:172-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27125257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacotherapy. 2019 Jun;39(6):677-688</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30351459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Am Acad Child Adolesc Psychiatry. 1993 Sep;32(5):1065-72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8407753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biol Psychiatry. 2019 Oct 15;86(8):587-598</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31182215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Am Acad Child Adolesc Psychiatry. 2010 Oct;49(10):1001-10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20855045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schizophr Res. 2019 Aug;210:143-148</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31182321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Pharmacol. 2008 Jan 14;578(2-3):148-58</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17963743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Psychiatr Pract. 2014 Nov;20(6):428-37</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25406047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Am Acad Child Adolesc Psychiatry. 2015 Jul;54(7):532-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26088654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychopharmacology (Berl). 1986;90(3):295-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3097715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br Med J. 1980 Mar 8;280(6215):684-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7363020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curr Psychiatry Rep. 2018 Mar 12;20(3):17</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29527636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs R D. 2013 Jun;13(2):119-28</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23615868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drug Metab Dispos. 2010 Sep;38(9):1393-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20570945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacopsychiatry. 2018 Jan;51(1-02):9-62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28910830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Clin Psychiatry. 2012 Feb;24(1):23-37</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22303520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Child Adolesc Psychopharmacol. 2019 May;29(4):285-304</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30942617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paediatr Drugs. 2018 Apr;20(2):181-194</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29098603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World J Biol Psychiatry. 2018 Apr;19(3):162-174</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29493375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Learn Mem. 2006 Nov-Dec;13(6):770-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17101879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CNS Drugs. 2018 Mar;32(3):289-301</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29557078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Psychiatry. 1971 Apr;127(10):1321-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5549923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacokinet. 2001;40(10):753-72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11707061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacotherapy. 1999 Jun;19(6):746-52</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10391421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drug Metab Dispos. 2013 Jan;41(1):197-205</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23104969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1971 Mar-Apr;12(2):259-62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4396632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacology. 2017;99(1-2):84-88</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27816979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Pharmacol Exp Ther. 1982 Mar;220(3):609-15</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6121048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prim Care Companion CNS Disord. 2014;16(3):null</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25317367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Am Acad Child Adolesc Psychiatry. 1999 Feb;38(2):112-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9951206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 2019 Jul;106(1):94-102</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30801677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Psychiatry. 1983 Feb;140(2):241-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6849446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs R D. 2015 Jun;15(2):175-85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25862215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacokinet. 2005;44(6):571-90</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15910008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biochem J. 1970 Feb;116(3):425-35</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4985156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birth Defects Res. 2019 Mar 1;111(4):229</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30729747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dev Med Child Neurol. 1988 Apr;30(2):267-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3133263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychopharmacol Bull. 1991;27(4):411-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1687612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Child Adolesc Psychiatr Nurs. 2017 Aug;30(3):126-132</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29349890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 2002 Apr;42(4):450-60</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11936571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Psychopharmacol. 2014 Mar;28(3):179-203</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24526134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs R D. 2013 Mar;13(1):53-61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23519656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Child Adolesc Psychopharmacol. 2001 Summer;11(2):193-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11436960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Atten Disord. 2018 Feb;22(3):203-228</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27664125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Child Adolesc Psychopharmacol. 1998;8(2):143-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9730080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Child Adolesc Psychopharmacol. 2005 Feb;15(1):12-25</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15741782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychiatr Serv. 2018 Jun 1;69(6):716-722</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29540121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Am Acad Child Adolesc Psychiatry. 1998 Nov;37(11):1128-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9808919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Drug Investig. 2013 Apr;33(4):243-54</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23512639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Psychopharmacol. 2019 Mar/Apr;39(2):124-128</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30707118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Psychiatry. 2003 Jun;160(6):1071-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12777264</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
